Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Sci Rep. 2022 Mar 14;12(1):4355. doi: 10.1038/s41598-022-08362-2.
Cutaneous angiosarcomas is a rare cancer with poor prognoses. The common radiotherapy techniques that have been reported so far are two pairs of lateral X-ray and electron fields. However, it is quite difficult to irradiate scalp angiosarcomas (SAs) homogeneously with this technique. In this study, safety, effectiveness, and risk factors were assessed for localized SAs ≥ 5 cm treated with intensity-modulated radiotherapy (IMRT) or volumetric modulated arc therapy (VMAT) with boluses. Sixty-eight angiosarcoma patients who had received radiotherapy in our institution between January 2007 and November 2020 were retrieved from our radiotherapy database. Of these patients, 27 localized SA patients were included in the retrospective analysis. The 2-year overall survival, local progression-free rate, and distant metastases-free survival were 41.8%, 48.4%, and 33.1%. All the patients experienced acute radiation dermatitis ≥ grade 2, with18 (66.7%) ≥ grade 3. No nodule lesion was a significant unfavorable predictive factor of acute radiation dermatitis ≥ grade 3. Tumor bleeding at the initiation of radiotherapy and tumor invasion to the face were significant predictive factors of overall survival, and tumor bleeding at the initiation of radiotherapy was also a significant predictive factor of local progression-free rate.
皮肤血管肉瘤是一种预后不良的罕见癌症。迄今为止,报道的常见放疗技术有两对侧方 X 射线和电子野。然而,用这种技术均匀照射头皮血管肉瘤(SA)相当困难。在这项研究中,我们评估了使用局部剂量递增的调强放疗(IMRT)或容积旋转调强放疗(VMAT)治疗≥5cm 局限性 SA 的安全性、有效性和危险因素。从我们的放疗数据库中检索了 2007 年 1 月至 2020 年 11 月在我院接受放疗的 68 例血管肉瘤患者,其中 27 例局限性 SA 患者纳入回顾性分析。2 年总生存率、局部无进展生存率和远处无转移生存率分别为 41.8%、48.4%和 33.1%。所有患者均发生急性放射性皮炎≥2 级,其中 18 例(66.7%)≥3 级。无结节病变是急性放射性皮炎≥3 级的显著不良预测因素。放疗开始时肿瘤出血和肿瘤侵犯面部是总生存的显著预测因素,放疗开始时肿瘤出血也是局部无进展生存率的显著预测因素。